Close Menu

BioMérieux: Kirk Ririe

Sep 06, 2019

Kirk Ririe, has retired from his position as bioMérieux's chief innovation officer and member of the firm's executive committee. Ririe will continue to act as a scientific advisor to the chairman and CEO.

More Like This

Sep 17, 2019

Ontera: Mark Rose and Raparti Swayambhu

Nanopore diagnostics firm Ontera has appointed Mark Rose as VP of product management and Raparti Swayambhu as VP of software.

Rose will be responsible for development, launch, and commercial activities of the firm's diagnostic product portfolio. He comes from Google, where he was a product lead and helped launch the Nest brand of internet-connected devices for the home. He has also worked at Motorola and Facebook. He holds an MBA from the Craig School of Business at California State University, Fresno.

Swayambhu will oversee the firm's software development, enterprise IT, and data science teams. He brings more than 20 years of experience in software development and has held technical leadership roles at Sema4 and Genentech, among other firms. He holds a master's degree in computer science from Carnegie Mellon University.

Sep 13, 2019

QuantuMDx: Neil Butler

UK-based QuantuMDx has appointed Neil Butler as its non-executive director. Butler currently serves on the board of Nidor Dx, Radisens, and Spectromics. He previously served as chair and non-executive director for Atlast Genetics/Binx Health and Genomic Vision. 

Sep 12, 2019

ACMG Foundation: Brynn Levy, David Tilstra

Brynn Levy and David Tilstra have been elected to the board of directors of the ACMG Foundation for Genetic and Genomic Medicine, a nonprofit organization that facilitates the integration of genetics and genomics into medical practice.

Levy is a professor in the Department of Pathology & Cell Biology at Columbia University Irving Medical Center and co-director of the department's division of personalized genomic medicine. In addition, he is the medical director of the clinical cytogenetics laboratory of New York Presbyterian Hospital.

Tilstra is president emeritus of CentraCare Clinic. Until the end of 2018, he was the clinic's president, and before that, its medical director. Tilstra holds an MBA from the University of Colorado Denver, an MD from the University of Iowa College of Medicine, and an undergraduate degree in chemistry from Northwestern College of Orange City.

Sep 10, 2019

Epic Sciences: Joel Smith

San Diego-based Epic Sciences has appointed Joel Smith as its general counsel and executive VP of corporate development. Prior to Epic Sciences, Smith acted as managing counsel of Qualcomm Life. Smith has also served as senior executive and general counsel at biotech and life science companies including BioQ, Triad Therapeutics, and Sientra.


Sep 10, 2019

Quest Diagnostics: Manuel Méndez

Quest Diagnostics has named Manuel Méndez its senior VP and chief commercial officer, effective Oct. 7. Méndez is leaving Qiagen, where he currently is senior VP, global commercial operations and a member of the executive committee. Prior to joining Qiagen, he was executive VP Americas for BioMérieux.

Sep 09, 2019

Specific Diagnostics: Eric Stang

Eric Stang has joined the advisory board of Specific Diagnostics, a Mountain View, California-based in vitro diagnostics company. Stang is currently the CEO and chairman of Ooma and a member of the board of directors of Rambus. He most recently served as director of InvenSense, a MEMS semiconductor company, and as director of Solta Medical, a medical aesthetics company. 

Sep 09, 2019

Celcuity: Eric Lindquist

Cell analysis company Celcuity has named Eric Lindquist its chief business officer. He had been global vice president of oncology and rare disease at Natera. Prior to that, he was global vice president of customer and companion diagnostics at Asuragen, as well as director of business development and alliances for companion diagnostics at Roche Diagnostics. 

Sep 09, 2019

Luminex: Dijuana Lewis

Luminex has elected Dijuana Lewis as an independent director to its board of directors, to the board's compensation and nominating committee, and to its corporate governance committee.

In a filing with the US Securities and Exchange Commission, Luminex reported that Lewis has served on various nonprofit and advisory boards and has consulted on healthcare related matters since her retirement from Aetna in April 2016.

She served Aetna as executive vice president, consumer products and enterprise marketing from October 2013 to April 2016. Prior to that, she served as senior vice president, health and wellness for Walmart Stores from March 2011 to October 2013. Further, Lewis previously served in a number of executive level positions of increasing responsibility with Anthem/Wellpoint from August 1994 to January 2011, including as the executive vice president and chief executive officer of its comprehensive health solutions division from October 2007 to January 2011.

Sep 06, 2019

Shield Diagnostics: David Esposito

David Esposito has been appointed to the board of directors of Shield Diagnostics, a San Jose, California-based rapid molecular diagnostics firm developing assays for resistance-guided therapy. Esposito is currently CEO of ONL Therapeutics. He formerly served as CEO of Armune BioScience, a company that was sold to Exact Sciences in 2017, and he also served as President of Phadia US, an allergy and autoimmune diagnostics firm, playing a pivotal role in selling the business to Thermo Fisher Scientific in 2011.

Sep 05, 2019

Thermo Fisher Scientific: Debora Spar, Patrick Durbin, Gianluca Pettiti

Debora Spar has been elected as a director of Thermo Fisher Scientific. She is a professor of business administration at Harvard Business School. Previously, she was president and CEO of Lincoln Center for the Performing Arts and before that, president of Barnard College. Spar holds a PhD in government from Harvard University and a BSc from Georgetown University.

Also, Patrick Durbin, senior vice president at Thermo Fisher Scientific, has decided to leave the company, effective Oct. 1. He will be replaced by Gianluca Pettiti, president of the firm's biosciences business. Prior to that, Pettiti was president of Thermo Fisher China.

Sep 05, 2019

Todos Medical: Jorge Leon

Todos Medical has appointed Jorge Leon as a medical advisor to assist it with clinical development, regulatory strategy, and fundraising.

Leon holds a Ph.D. in cellular and molecular biology from New York University and completed his postdoctoral studies at the German Cancer Research Center in Heidelberg and Columbia University in New York. His subsequent academic research at Columbia University focused on developing monoclonal antibody-based tumor marker assays and radio-immunoimaging devices that are in wide use, according to Todos Medical.

In the early 1990s, Leon played an integral role in establishing and leading the molecular diagnostics laboratories at Quest Diagnostics. He spent 12 years developing Quest’s molecular diagnostics strategy as its director of molecular diagnostics, senior director of biotechnology development, and vice president of applied genomics.

In 2003, Leon founded Leomics Associates, a consulting firm established to help companies and academic institutions develop molecular diagnostics and personalized medicine products.

Sep 05, 2019

Farcast Biosciences: Maneesh Arora

Maneesh Arora has joined Boston-based diagnostics firm Farcast Biosciences as president and CEO. Arora previously served as COO and a member of the board of directors of Exact Sciences. He also previously was CFO of Third Wave Technologies, which was acquired in 2008 by Hologic for $582 million. Farcast, formerly called Mitra Biotech, has developed an ex vivo platform for evaluating tumor response to drug treatments.

Sep 03, 2019

ACMG: Maximilian Muenke

Maximilian Muenke has been named CEO of the American College of Medical Genetics and Genomics, succeeding Michael Watson. He will take up his new position on Oct. 7. Since 2000, Muenke has served as senior investigator, head of the human development section, and chief of the medical genetics branch at the National Human Genome Research Institute. Previously, he was a faculty member at the University of Pennsylvania. He holds an MD degree from the Free University of Berlin School of Medicine in Germany.

Aug 30, 2019

Lunaphore: Joseph Bernardo

Lausanne, Switzerland-based Lunaphore Technologies has appointed Joseph Bernardo chairman of its board of directors. Bernardo has a leadership background spanning the diagnostic value chain, including laboratory management, sales, service, marketing, distribution, operations, and R&D. Bernardo has held four president positions at Thermo Fisher Scientific, including in the divisions of Next Generation Sequencing, Immunodiagnostics, Anatomic Pathology, and Fisher Healthcare. In addition to his operational executive experience in diagnostics, Bernardo has significant M&A experience and has been involved in more than 40 due diligence assessments, acquisitions, and company integrations, Lunaphore said.

Aug 29, 2019

Natera: Rowan Chapman

Rowan Chapman has joined the board of directors of Natera. Most recently, she was head of Johnson & Johnson Innovation for Western North America, Australia, and New Zealand; head of precision diagnostics at GE Healthcare Life Sciences; and managing director of new business creation and head of healthcare investing at GE Ventures. Prior to that, she was a partner at Mohr Davidow Ventures. Chapman holds a BA in biochemistry and a PhD in biochemistry and molecular biology from the University of Cambridge.